Literature DB >> 27367867

Low Use of Oral Anticoagulant Prescribing for Secondary Stroke Prevention: Results From the Ontario Stroke Registry.

Reema Shah1, Shudong Li, Melissa Stamplecoski, Moira K Kapral.   

Abstract

BACKGROUND: Oral anticoagulation reduces the risk of stroke in atrial fibrillation but is often underused.
OBJECTIVES: To identify factors associated with oral anticoagulant prescribing and adherence after stroke or transient ischemic attack (TIA). RESEARCH
DESIGN: Retrospective cohort study using linked Ontario Stroke Registry and prescription claims data.
SUBJECTS: Consecutive patients with atrial fibrillation and ischemic stroke/TIA admitted to 11 stroke centers in Ontario, Canada between 2003 and 2011. MEASURES: We used modified Poisson regression models to determine predictors of anticoagulant prescribing and multiple logistic regression to determine predictors of 1-year adherence.
RESULTS: Of the 5781 patients in the study cohort, 4235 (73%) were prescribed oral anticoagulants at discharge. Older patients were less likely to receive anticoagulation [adjusted relative risk (aRR) for each additional year=0.997; 95% confidence interval (CI), 0.995-0.998], as were those with TIA compared with ischemic stroke (aRR=0.904; 95% CI, 0.865-0.945), prior gastrointestinal bleed (aRR=0.778; 95% CI, 0.693-0.873), dementia (aRR=0.912; 95% CI, 0.856-0.973), and those from a long-term care facility (aRR=0.810; 95% CI, 0.737-0.891). After limiting the sample to those without obvious contraindications to anticoagulation, age, dementia, and long-term care residence continued to be associated with lower prescription of oral anticoagulants. One-year adherence to therapy was similar across most patient groups.
CONCLUSIONS: Age, dementia, and long-term care residence are predictors of lower oral anticoagulant use for secondary stroke prevention and represent key target areas for quality improvement initiatives.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27367867     DOI: 10.1097/MLR.0000000000000589

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  6 in total

1.  Mortality After Ischemic Stroke in Patients with Alzheimer's Disease Dementia and Other Dementia Disorders.

Authors:  Eva Zupanic; Mia von Euler; Bengt Winblad; Hong Xu; Juraj Secnik; Milica Gregoric Kramberger; Dorota Religa; Bo Norrving; Sara Garcia-Ptacek
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 2.  Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke.

Authors:  Daniela Rohde; Niamh A Merriman; Frank Doyle; Kathleen Bennett; David Williams; Anne Hickey
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

3.  Comparison of the Quality of Chronic Disease Management Between Adults With and Without Dementia.

Authors:  Hiroshi Gotanda; Teryl Nuckols; Kanon Mori; Yusuke Tsugawa
Journal:  JAMA Netw Open       Date:  2021-05-03

Review 4.  Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta-analysis.

Authors:  Min Yang; Hang Cheng; Xia Wang; Menglu Ouyang; Sultana Shajahan; Cheryl Carcel; Craig Anderson; Espen Saxhaug Kristoffersen; Yapeng Lin; Else Charlotte Sandset; Xiaoyun Wang; Jie Yang
Journal:  Brain Behav       Date:  2022-09-06       Impact factor: 3.405

5.  The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: A drug utilization study using claims data in Japan.

Authors:  Kiyoshi Kubota; Nobuhiro Ooba; Yukari Kamijima; Kuniyasu Sato; Daisuke Koide
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

6.  Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders.

Authors:  Eva Zupanic; Milica G Kramberger; Mia von Euler; Bo Norrving; Bengt Winblad; Juraj Secnik; Johan Fastbom; Maria Eriksdotter; Sara Garcia-Ptacek
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.